We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Manipulating Ribozymes to Control Gene Activity

By Biotechdaily staff writers
Posted on 12 Oct 2004
A new study explores the use of ribozymes--catalytic RNA that cleaves certain target RNA and thus prohibits gene function--in conjunction with specific drugs to control gene expression as a possible treatment for chronic diseases.

Investigators at Harvard Medical School (Boston, MA, USA) evaluated hundreds of known ribozymes and found two that functioned well in human cells. More...
When the ribozymes were inserted into cells, they shut down gene activity by cleaving RNA and preventing protein synthesis. Next, the investigators searched for drugs that would inhibit ribozyme activity and allow the gene to continue to function. Two likely candidates were found.


To demonstrate how the system could function, the investigators inserted the gene for luciferase along with an embedded ribozyme into the retinas of mice. With no treatment, luciferase was not produced, but after treatment with a ribozyme inhibitor, luciferase could be detected. These findings were published in the September 23, 2004, issue of Nature.

"Perhaps the most exciting aspect of the new work is that, in conjunction with other technologies, we will likely be able to ‘tailor' gene regulation systems to respond to any drug or chemical,” said senior author Dr. Richard Mulligan, professor of genetics at Harvard Medical School. "Ultimately, the system should also enable the ‘release' of a therapeutically useful protein in response to changing concentrations of chemicals in cells. For instance, it may be possible to develop a gene therapy whereby cells are engineered to secrete insulin in response to a rise in glucose. Such ‘biological sensing' could have a wide range of applications.”



Related Links:
Harvard Medical School

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Automatic CLIA Analyzer
Shine i6000
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image:  Estimates suggest that 30–50% of CKD cases go undiagnosed in high‑income countries, with even higher proportions likely in middle‑ and lower‑income countries (Image Credit: Shutterstock)

Routine Urine Protein Testing Identifies Undiagnosed Chronic Kidney Disease

Chronic kidney disease (CKD) is a major cause of mortality worldwide and often progresses silently until advanced stages. Despite the availability of simple urine and blood tests, many cases remain undetected,... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.